Science Corp. raises $230M to commercialize PRIMA visual implant
Context and Chronology
Science Corporation announced a fresh capital infusion that will accelerate commercialization of a retinal brain–interface system known as PRIMA. The financing round netted $230M, lifting the startup’s post‑round valuation to roughly $1.25B and bringing total disclosed funding to $490M. Founder Max Hodak framed the raise as the necessary resource to move from trials into regulated markets; later references use Mr. Hodak for clarity. Management targets regulatory clearance in Europe and a product launch soon after.
Clinically, Science reports outcomes from a controlled program covering 47 patients treated in Europe and the United States, with about 80% achieving meaningful visual gains such as reading letters. The company has submitted for a CE mark and expects a decision by mid-2026, with Germany identified as the initial commercial entry due to accelerated access mechanisms. Parallel regulatory discussions in the United States remain active but unresolved, and the trial cohort will broaden to include Stargardt disease and retinitis pigmentosa.
The PRIMA technology was obtained after an asset acquisition from a European developer and then advanced in subsequent studies by Science’s team. The company is also advancing two adjacent platforms: a biohybrid neural interface that integrates engineered neurons with a surface device, and Vessel, a miniaturized organ perfusion program aimed at decentralized transport and storage. New and returning backers on the cap table include Lightspeed, Khosla Ventures, Y Combinator, Quiet Capital and IQT, each bringing capital and strategic connections for commercialization and, in IQT’s case, potential government applications.
Read Our Expert Analysis
Create an account or login for free to unlock our expert analysis and key takeaways for this development.
By continuing, you agree to receive marketing communications and our weekly newsletter. You can opt-out at any time.
Recommended for you
China BCI Industry Accelerates Toward Commercial Scale
China’s BCI ecosystem is shifting from lab projects to market-ready products as policy, clinical throughput, and targeted capital converge. Key signals: an 11.6 billion CNY brain science fund, >50 implantable trials by mid‑2025, and $48M–$287M financings that together compress commercialization timelines for neurotech.
AI-native imaging reshapes cardiac diagnostics as VentriPoint advances commercial rollout
A wave of software-first medical imaging innovations is shifting care models away from large MRI suites toward cloud-enabled, subscription services; VentriPoint is moving from R&D into commercialization with fresh capital, executive hires and partnerships aimed at proving economic value. Parallel moves from Butterfly, RadNet, Nanox and OneMedNet show the sector unraveling traditional hardware economics while pushing regulatory and distribution milestones that will determine who scales first.
Apptronik secures $520M to accelerate commercial rollout of Apollo humanoids
Apptronik closed a $520 million financing at about a $5 billion valuation, expanding its Series A to $935 million and tapping Google DeepMind technology to ready its Apollo humanoid for broader deployment. The capital will fund production scale-up, expanded facilities in Austin and California, and deeper software and fleet-data work to improve autonomy amid competitive pressure from lower-priced and fast-to-market robotic entrants.
Thrive Capital raises a $10 billion fund to scale AI, space, robotics and life‑science bets
Thrive Capital closed a new fund that tops $10 billion, roughly double its prior vehicle, and declined additional commitments totaling multiple billions. The raise concentrates resources for investments in AI applications and infrastructure, space, robotics and life sciences — a dynamic that both intensifies competition for top startups and raises governance, vendor‑access and regulatory questions around concentrated ownership of AI leaders.
Cerebras Raises $1 Billion in New Funding, Valued at $23 Billion
Cerebras closed a $1.0 billion growth round at a $23.0 billion valuation to speed commercialization of its wafer‑scale AI processors and systems. The capital is aimed at engineering tapeouts, securing foundry throughput and packaging/yield improvements, and maturing toolchains and interoperability to win enterprise deployments amid a crowded AI‑hardware funding wave.
Flapping Airplanes raises $180M to pursue radical data‑efficient AI
Flapping Airplanes launched with a $180M seed to build foundation models that drastically cut data needs by pursuing algorithmic shifts inspired by the brain rather than scaling alone. The lab argues that radically better sample efficiency—publicly targeting gains as large as 1000x —could unlock robotics and scientific domains that are currently data‑starved, and it plans to prioritize cheap, small‑scale experiments before committing heavy compute.
Bluprynt Raises $4.25M Seed to Embed Crypto Compliance
Bluprynt closed a $4.25M seed round led by Valor Capital Group , with strategic checks from Coinbase Ventures and Robinhood , to accelerate onchain compliance tooling. The raise signals institutional investors backing regulatory-aligned infrastructure as U.S. agencies operationalize new stablecoin and digital-asset rules.
FDA Clears First Human Trial of ER‑100, a Reprogramming-Based Glaucoma Therapy
Life Biosciences has received FDA permission to start a first-in-human study of ER‑100, a gene therapy that aims to partially reprogram cells to treat glaucoma by delivering a single viral dose into one eye. The trial uses built-in molecular controls to limit dedifferentiation; its safety and efficacy readouts will be a decisive signal for the broader longevity-biotech field.